| Liu, Wen |
NCT06338995: A Study of Lebrikizumab (LY3650150) in Adult Participants With Chronic Rhinosinusitis and Nasal Polyps Treated With Intranasal Corticosteroids (CONTRAST-NP) |
|
|
| Recruiting | 3 | 510 | Europe, Canada, Japan, US, RoW | LY3650150, Placebo, Standard therapy for INCS | Eli Lilly and Company | Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) | 10/26 | 02/27 | | |
| Completed | 3 | 264 | Europe, Japan, US, RoW | Depemokimab (GSK3511294), Placebo | GlaxoSmithKline | Nasal Polyps | 07/24 | 08/24 | | |
|
NCT05865496: A Study to Evaluate 611 in Patients With Chronic Rhinosinusitis With Nasal Polyps |
|
|
| Active, not recruiting | 2 | 90 | RoW | 611, Placebo | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | Sinusitis, Nasal Polyps, Polyps | 05/24 | 07/24 | | |
NCT06451640: A Extension Clinical Study of TQC2731 Injection in the Treatment of Chronic Sinusitis With Nasal Polyps |
|
|
| Recruiting | 2 | 60 | RoW | 210mg of TQC2731 injection, 420mg of TQC2731 injection | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Chronic Rhinosinusitis With Nasal Polyps | 05/25 | 02/26 | | |
NCT06439381: Long-term Safety and Efficacy of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps |
|
|
| Recruiting | 2 | 120 | RoW | 300mg/600mg of TQH2722 injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Rhinosinusitis | 10/25 | 11/25 | | |
NCT06089278: A Clinical Study of TQH2722 Injection in the Treatment of Chronic Sinusitis With or Without Nasal Polyps. |
|
|
| Recruiting | 2 | 160 | RoW | 300mg of TQH2722 injection, 600mg of TQH2722 injection, TQH2722 injection matching placebo | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Sinusitis | 05/25 | 05/25 | | |
NCT06036927: A Clinical Study of TQC2731 Injection in the Treatment of Chronic Rhinosinusitis With Nasal Polyps |
|
|
| Recruiting | 2 | 80 | RoW | TQC2731 injection, TQC2731 matching placebo | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Chronic Sinusitis, Nasal Polyps | 07/25 | 09/25 | | |
| SONG, Dan |
| Recruiting | N/A | 50 | RoW | Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder | Abbott Medical Devices | Non-Valvular Atrial Fibrillation | 01/27 | 01/30 | | |
| Wang, Xiaoyun |
NCT05525637: Safety and Efficacy Study of YZJ-1139 in Insomnia Disorder |
|
|
| Recruiting | 3 | 1041 | RoW | YZJ-1139 20mg, YZJ-1139 40mg, Placebo | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Insomnia Disorder | 12/24 | 12/24 | | |
| HUANG, Zhijun |
REVO, NCT05007145: PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 92 | RoW | PD-1 inhibitor, Albumin-Bound Paclitaxel, Cisplatin, Radiation | Fujian Cancer Hospital, Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Esophageal Neoplasms, Esophageal Squamous Cell Carcinoma | 08/23 | 08/23 | | |
| Recruiting | N/A | 50 | RoW | Left Atrial Appendage (LAA) closure procedure with Amplatzer Amulet LAA occluder | Abbott Medical Devices | Non-Valvular Atrial Fibrillation | 01/27 | 01/30 | | |
| Wang, Shaojun |
NCT03789760: The Clinical Trial of Chinese Herbal Medicine (SaiLuoTong) Capsule |
|
|
| Completed | 3 | 493 | RoW | SaiLuoTong capsule, The effects of SaiLuoTong capsule on VaD, placebo | Shineway Pharmaceutical Co.,Ltd | Vascular Dementia | 03/24 | 05/24 | | |
| Shen, Lu |
NCT05908695: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | 4 | 1312 | RoW | GV-971, Placebo | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer's Disease | 06/29 | 12/29 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder |
|
|
| Completed | 3 | 206 | RoW | Daridorexant, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Insomnia Disorder | 04/24 | 05/24 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| HU, Wenli |
| Active, not recruiting | 4 | 800 | RoW | Sodium Oligomannate Capsules (GV-971) | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 06/25 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Okhravi, Hamid |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Terminated | 3 | 1027 | Europe, Canada, Japan, US, RoW | Aducanumab, BIIB037, Aducanumab-avwa, Aduhelm, Placebo | Biogen, Biogen Idec Research Limited | Alzheimer's Disease | 08/24 | 08/24 | | |
| Completed | N/A | 466 | Canada, US | | Optina Diagnostics Inc., Eastern Virginia Medical School, The Cleveland Clinic, University of Washington, Sunnybrook Research Institute | Alzheimer Disease, Mild Cognitive Impairment, Mild Dementia | 07/24 | 07/24 | | |
| Guo, Aihong |
NCT05908695: An Efficacy and Safety Study of Sodium Oligomannate (GV-971) for the Treatment of Alzheimer's Disease |
|
|
| Recruiting | 4 | 1312 | RoW | GV-971, Placebo | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer's Disease | 06/29 | 12/29 | | |
BHV3000-318, NCT05371652: A Study to Learn About the Long-term Safety of Rimegepant for the Acute Treatment of Migraine in Chinese Participants |
|
|
| Completed | 3 | 241 | RoW | Rimegepant 75mg Orally Disintegrating Tablets (ODT) | Pfizer, Bioshin (Shanghai) Consulting Services Co., Ltd | Acute Migraine | 02/24 | 02/24 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
| Recruiting | 3 | 2100 | Europe, Canada, Japan, US, RoW | Rimegepant/BHV3000, Matching placebo | Pfizer | Pediatric Migraine | 01/29 | 01/29 | | |
| Wang, Weiwei |
| Completed | 3 | 1412 | RoW | Injection of recombinant human tissue plasminogen kinase derivatives, Reteplase, brand name: Ruitongli, r-PA, Recombinant human tissue plasminogen activator, Alteplase, brand name: Actilyse, rt-PA | Angde Biotech Pharmaceutical Co., Ltd., Beijing Tiantan Hospital | Acute Ischemic Stroke | 06/23 | 06/23 | | |
| Feng, Meijiang |
| Active, not recruiting | 4 | 800 | RoW | Sodium Oligomannate Capsules (GV-971) | Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Alzheimer Disease | 01/25 | 06/25 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Gong, Xiaoying |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Xu, Qiaorong |
NCT06010693: A Study of Daridorexant in Chinese Patients With Insomnia Disorder |
|
|
| Completed | 3 | 206 | RoW | Daridorexant, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Insomnia Disorder | 04/24 | 05/24 | | |
| Yu, Binke |
| No trials found |
